scholarly journals Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy

2018 ◽  
Vol 11 (1) ◽  
pp. 29-32 ◽  
Author(s):  
Taku Fujimura ◽  
Kayo Tanita ◽  
Yota Sato ◽  
Yumi Kambayashi ◽  
Sadanori Furudate ◽  
...  
Keyword(s):  
Immune Response ◽  
T Cell ◽  
Mycosis Fungoides ◽  
Successful Treatment ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Antitumor Immune Response ◽  
Cutaneous T Cell Lymphoma ◽  
Lymphoma Cells ◽  
Dependent Cell

Mogamulizumab induces cytotoxicity against CCR4+ lymphoma cells by antibody-dependent cell-mediated cytotoxicity in advanced cutaneous T-cell lymphoma patients. Since the efficacy of mogamulizumab in mycosis fungoides (28.6%) is lower than that in Sézary syndrome (47.1%), reagents that enhance the antitumor immune response induced by mogamulizumab are needed to further optimize its use for the treatment of erythrodermic mycosis fungoides. In this report, we present a case of erythrodermic mycosis fungoides successfully treated with mogamulizumab followed by etoposide monotherapy.

scholarly journals Successful Treatment of Primary Cutaneous Peripheral T-Cell Lymphoma Presenting Acquired Ichthyosis with Oral Bexarotene Monotherapy

2017 ◽  
Vol 10 (1) ◽  
pp. 328-332 ◽  
Author(s):  
Kayo Tanita ◽  
Taku Fujimura ◽  
Yota Sato ◽  
Takanori Hidaka ◽  
Sadanori Furudate ◽  
...  
Keyword(s):  
T Cell ◽  
Mycosis Fungoides ◽  
Successful Treatment ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Hematological Disease ◽  
Lymphoma Cells ◽  
Peripheral T Cell Lymphoma ◽  
Not Otherwise Specified

Acquired ichthyosis (AI) is a reactive cutaneous manifestation that can be associated with malignant hematological disease, including cutaneous T-cell lymphoma (CTCL). Since it is difficult to distinguish AI from ichthyosiform mycosis fungoides, to select the treatment for CTCL with ichthyosis-like appearance and to evaluate its efficacy is sometimes challenging. In this report, we describe a case of primary cutaneous peripheral T-cell lymphoma not otherwise specified presenting AI successfully treated with oral bexarotene. In the present case, the administration of oral bexarotene was not only effective for lymphoma cells infiltrating ulcers and nodules, but it also eliminated AI.

scholarly journals PRO25 Healthcare Resource Use in Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma: Results from a UK-Based Clinician Questionnaire

2020 ◽  
Vol 23 ◽  
pp. S693-S694
Author(s):  
J. Scarisbrick ◽  
F. Schmidt ◽  
M.M. Turini ◽  
P. D'agostino ◽  
D. Summers ◽  
...  
Keyword(s):  
T Cell ◽  
Mycosis Fungoides ◽  
Resource Use ◽  
Healthcare Resource ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Healthcare Resource Use

Cutaneous T-Cell Lymphoma: Mycosis Fungoides and Sézary Syndrome

2019 ◽  
pp. 221-246
Author(s):  
Timothy J. Voorhees ◽  
Edith V. Bowers ◽  
Christopher R. Kelsey ◽  
Yara Park ◽  
Anne W. Beaven
Keyword(s):  
T Cell ◽  
Mycosis Fungoides ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Cutaneous T Cell Lymphoma

scholarly journals Apoptosis Induction by SAHA in Cutaneous T-Cell Lymphoma Cells Is Related to Downregulation of c-FLIP and Enhanced TRAIL Signaling

2012 ◽  
Vol 132 (9) ◽  
pp. 2263-2274 ◽  
Author(s):  
Nadya Al-Yacoub ◽  
Lothar F. Fecker ◽  
Markus Möbs ◽  
Michael Plötz ◽  
Frank K. Braun ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Apoptosis Induction ◽  
Lymphoma Cells ◽  
Trail Signaling

scholarly journals Demonstration of antibodies to human T-cell lymphotropic virus-I tax in patients with the cutaneous T-cell lymphoma, mycosis fungoides, who are seronegative for antibodies to the structural proteins of the virus

Blood ◽  
1996 ◽  
Vol 88 (8) ◽  
pp. 3004-3009 ◽  
Author(s):  
BA Pancake ◽  
EH Wassef ◽  
D Zucker-Franklin
Keyword(s):  
T Cell ◽  
Mycosis Fungoides ◽  
Mononuclear Cells ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Structural Proteins ◽  
Infected Cell Line ◽  
Cutaneous T Cell Lymphoma ◽  
Serologic Tests ◽  
Human T Cell

Although most patients with the cutaneous T-cell lymphoma, mycosis fungoides (MF), are seronegative for human T-cell lymphotropic virus-I or -II (HTLV-I/II) when tested by assays that measure only antibodies to the viral structural proteins, the majority of such patients harbor HTLV-I-related pol and tax proviral sequences that encode proteins not included in routinely used serologic tests. Tax mRNA has also been detected in their peripheral blood mononuclear cells (PBMC). Therefore, it seemed possible that these patients have antibodies to the tax protein. To investigate this, enzyme-linked immunosorbent assays (ELI-SAs) and Western blot assays were set up, using as antigens the full-length HTLV-I tax cloned from the prototypic HTLV-I-infected cell line, C91PL, and from PBMC of a MF patient, as well as a synthetic peptide made to the carboxy-terminal 20 amino acids of tax-I. Of 60 MF patients whose PBMC were shown to be positive for tax proviral DNA and mRNA, 50 (83%) were shown to have tax antibodies. The antigen derived from the MF patient was most useful in detecting such antibodies. These results demonstrate the need for including other HTLV-related antigens in addition to gag and env in serologic tests used to identify HTLV-infected individuals. The findings underscore the fact that individuals considered seronegative on the basis of currently used tests can be infected with HTLV.

Sign in / Sign up

Export Citation Format

Share Document